⌘K
t
| Date | 27 Jun 2025 |
| Time | 12:35:34 |
| Category | Miscellaneous |
| ID | 7905O |
27 June 2025
ProBiotix Health plc
("ProBiotix Health" or the "Company" or, together with its subsidiary, the "Group")
Result of AGM and Notice of Trading Update
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that at the AGM held earlier today, all resolutions were duly passed.
The full voting results will be available on the Company's website in due course at www.probiotixhealth-ir.com.
Momentum in the business continues to be strong, buoyed by increasing demand for our products. A trading update for the first six months of the current financial year will be issued on 15 July 2025.
For further information, please contact:
|
ProBiotix Health plc |
https://probiotixhealth-ir.com/ |
|
|
investors@probiotixhealth.com |
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
Peterhouse Capital Limited Aquis Corporate Adviser and Broker |
Tel: 020 7469 0930
|
|
Mark Anwyl Duncan Vasey |
|
|
|
|
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Notes to Editors:
ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix Health has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.